Komori
Earnings4599StemRIM Inc.Pharmaceuticals

Summary of Financial Results for the Third Quarter of the Fiscal Year Ending July 2026 [Japanese GAAP] (Non-consolidated)

For the cumulative third quarter, the Company recorded operating, ordinary and net losses, as it generated no business revenue, but the losses narrowed from the same period of the previous year. Meanwhile, total assets, net assets and the equity ratio declined from the end of the previous fiscal year due to the recognition of a quarterly net loss.

Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
27.455
¥ million
Wording
Avoiding a definitive answer
How definitive the wording is.

Results for this period

Third quarter1 August 2025–30 April 2026Non-consolidated (standalone)Japanese GAAP
Operating profit-1,484¥ million
Ordinary income-1,437¥ million
Net income attributable to owners of the parent-1,408¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Net income per share△¥22.51
Financial position at period-end
Total assets6,357¥ million
of which net assets 6,125 ¥ millionEquity ratio 72.4%vs. prior year-end -5.6pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Outlook and shareholder returns
Full-year earnings forecast
Net SalesNot disclosed
Operating profitNot disclosed
Ordinary incomeNot disclosed
Net incomeNot disclosed
ReasonNot provided because it is currently difficult to reasonably calculate a full-year earnings forecast
Annual Dividend Forecast¥0 → ¥0
Factors Behind Changes in Business Performance

The Company generated no business revenue. Research and development expenses were ¥1,119,681 thousand (¥1,077,453 thousand in the same period of the previous year), while selling, general and administrative expenses were ¥364,633 thousand (¥434,316 thousand in the same period of the previous year). Non-operating income was ¥46,592 thousand (¥730 thousand in the same period of the previous year), reflecting increases in interest income, dividend income and subsidy income, among other items.

Disclosure regarding the going concern assumption

No applicable matters

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsAt the extraordinary general meeting of shareholders scheduled for 29 July 2026, the Company plans to submit a proposal for a capital reduction without compensation, reducing capital from ¥85,755,000 by ¥75,755,000 to ¥10,000,000. The entire reduction amount is scheduled to be transferred to the capital reserve, with no change planned to the total number of issued shares or net assets. The effective date is scheduled for 30 July 2026.
Breakdown of extraordinary income (loss)Extraordinary income Gain on reversal of subscription rights to shares ¥30,342 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand
Depreciation and amortization¥31,551 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End62,681,200
Treasury Shares at Period-End121
Results for this period
ItemDetails
Fiscal Period ClassificationThird quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 August 2025–30 April 2026
Operating profit¥-1,484 million
Ordinary income¥-1,437 million
Profit attributable to owners of the parent¥-1,408 million
Net income per share△¥22.51
Equity ratioEnd of the current fiscal period 72.4 / End of previous period 78
Total assets¥6,357 million
Net assets¥6,125 million
Full-year earnings forecastNet Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason Not provided because it is currently difficult to reasonably calculate a full-year earnings forecast
Annual Dividend Forecast¥0 → ¥0
Depreciation and amortization¥31,551 thousand
Breakdown of extraordinary income (loss)Extraordinary income Gain on reversal of subscription rights to shares ¥30,342 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand
Disclosure regarding the going concern assumptionNo applicable matters
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Material subsequent eventsAt the extraordinary general meeting of shareholders scheduled for 29 July 2026, the Company plans to submit a proposal for a capital reduction without compensation, reducing capital from ¥85,755,000 by ¥75,755,000 to ¥10,000,000. The entire reduction amount is scheduled to be transferred to the capital reserve, with no change planned to the total number of issued shares or net assets. The effective date is scheduled for 30 July 2026.
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End62,681,200
Treasury Shares at Period-End121
Factors Behind Changes in Business PerformanceThe Company generated no business revenue. Research and development expenses were ¥1,119,681 thousand (¥1,077,453 thousand in the same period of the previous year), while selling, general and administrative expenses were ¥364,633 thousand (¥434,316 thousand in the same period of the previous year). Non-operating income was ¥46,592 thousand (¥730 thousand in the same period of the previous year), reflecting increases in interest income, dividend income and subsidy income, among other items.
Items this document does not state (15)
Net SalesOperating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossChanges in the scope of consolidation

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company generated no business revenue. Research and development expenses increased from the same period of the previous year, while selling, general and administrative expenses decreased. Non-operating income also increased, mainly due to interest income, dividend income and subsidy income.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Third Quarter of the Fiscal Year Ending July 2026 [Japanese GAAP] (Non-consolidated) | StemRIM Inc. (4599) timely disclosure | Komori